DUBLIN–(BUSINESS WIRE)–The “Pharma and ESG – The Patient Perspective – The Views of 1,500 Patient Groups” report has been added to ResearchAndMarkets.com’s offering.
This analysis of patient-group opinions on ESG is based on two online surveys.
Patient-group familiarity with ESG
Although the terms ‘environmental, social, and governance’ are far from being universally embedded in the patient experience, or in healthcare culture, recognition of the purpose and definition of ESG is growing slowly among patient groups. 55% of patient groups responding to a 2021 survey stated that they “Did not know” about pharma’s ESG activities (a decrease from the 61% of respondent patient groups stating the same in the 2020 survey).
Many of these patient groups feel that pharma companies could do much more to communicate their ESG strategies to patient groups.
The importance of corporate ESG to patient groups
Only a few of the hundreds of commentaries received by the analyst from respondent patient groups describe pharma companies’ ESG activities as currently relevant to patients, and more a way for the industry to attract ethical investment.
Other respondent patient groups acknowledge the potential of ESG to support companies’ efforts at building more patient-centric measures of company performance. Such a patient-centric approach could boost a company’s corporate reputation- and perhaps even encourage more growth, they say.
“While all companies strive for profit, I think companies that collaborate and ethically/sustainably contribute to society will be remembered as growing and successful businesses.”
– National arthritis patient group, Korea
“Sustainability; ethical principles; non-political, win-win orientation in business- and, not in the least, patient centricity.”
– International blood-cancers patient group, Romania
Patient-group involvement in defining ESG criteria and assessing company performance at ESG
Looking to the future, many patient groups would like pharma companies to improve how they involve patient communities in defining patient-relevant ESG measures. A significant number (140) of respondent patient groups offered their own criteria for pharma’s ESG targets [details provided in the ‘Pharma and ESG – the Patient Perspective’ report]. Already, too, respondent patient groups are proving capable of measuring pharma’s aptitude at ESG.
“It is important to consider the environment, social, and governance of a pharmaceutical company, in regards to their reputation or brand, in order to evaluate if they are a good choice to work with.”
– National skin-conditions patient group, Australia
“Our organization assesses the improvement in the provision of healthcare by pharmaceutical companies a lot. That footprint goes beyond developing medicines, vaccines, supplies, and diagnostic tests, to meeting the medical needs that are pressing in the world. A lot of companies perform this work on sustainability and responsibility, but it is not central for them. Finally, we assess the environmental impacts that the companies cause.”
– National arthritis patient group, Brazil
“From an environmental perspective, our group is focused on how the company prioritizes their international efforts to work with the regions on key efforts to minimize and reduce the impacts on the environment, and public declarations of their commitment to help reduce climate change.”
– National mental-health patient group, Canada
This report examines:
Patient-group familiarity with ESG.
The importance of corporate ESG to patient groups.
Patient-group involvement in defining ESG criteria and assessing company performance at ESG.
How 47 pharma companies perform for ESG from a patient perspective.
Six pharma companies report on their ESG activities of importance to patients.
How 47 pharma companies perform for ESG – from a patient perspective
Patient groups were posed two key questions about individual pharma-company performance on ESG:
1.) “If you were asked to make a definite choice: Which three companies were ‘best’ in 2021 at… Adopting an ‘Environmental, Social, and Governance’ (ESG) agenda – from the perspective of the patients known to your organization?”
2.) “If you were asked to make a definite choice: Which three companies were ‘best’ in 2021 at… Communicating their performance at ‘Environmental, Social, and Governance’ (ESG) to patient groups?”
The six pharma companies which provided reports on their ESG activities of importance to patients
Boehringer Ingelheim
Gilead Sciences
Lundbeck USA
Merck & Co (known as MSD outside of the United States and Canada)
Pfizer
ViiV Healthcare
Who Should Read this Report?
Customer Types (Organizations)
Pharma companies
Biopharma companies
Regulatory authorities (e.g EMA, FDA)
NGOs and health charities (usually FOC) including Patient Groups
Research and academia
Job Titles/Functions for Pharma and Biopharma Organizations
Core:
Patient Relations
Corporate Reputation
Public Affairs
Professional Affairs
Patient Advocacy
Communications
Market Research
Secondary:
R&D
Health economics
Outcomes Research
Medical Affairs
Marketing
Brand teams
Market Access
Regulatory
Key Topics Covered:
Executive summary
Patient-group commentaries on ESG, and ESG targets
Six companies report on their ESG activities of importance to patients
Rankings of 47 pharma companies on their effectiveness at adopting and communicating their ESG agendas – according to patient groups familiar with the company
Rankings of 45 pharma companies on their effectiveness at adopting and communicating their ESG agendas – according to patient groups that work with the company
Rankings of 13 ‘big pharma’ companies on their effectiveness at adopting and communicating ESG agendas, according to patient groups familiar and working with the company
Appendix: Profiles of respondent patient groups
Companies Mentioned
AbbVie
Acorda Therapeutics
Almirall
Amgen
Astellas Pharma
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Bristol Myers Squibb
Chiesi Farmaceutici
CSL Behring
Daiichi Sankyo
Dr Reddy’s
Eisai
Eli Lilly
Ferring
Gedeon Richter
Gilead Sciences
Grifols
Grunenthal
GSK
Horizon Therapeutics
Ipsen
Janssen
LEO Pharma
Lundbeck
Menarini
Merck & Co (known as MSD outside of the United States and Canada)
Merck KGaA/EMD Serono
Mylan
Novartis
Novo Nordisk
Octapharma
Otsuka
Pfizer
Pierre Fabre
Roche/Genentech/Chugai
Sandoz
Sanofi
Servier
Sun Pharma
Takeda
Teva
UCB
Vertex
ViiV Healthcare
For more information about this report visit https://www.researchandmarkets.com/r/tlyo3b
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
